share_log

TRITON PACIFIC HEALTHCARE PARTNERS COMPLETES SALE OF BIOMATRIX SPECIALTY INFUSION PHARMACY

TRITON PACIFIC HEALTHCARE PARTNERS COMPLETES SALE OF BIOMATRIX SPECIALTY INFUSION PHARMACY

泰坦太平洋医疗合伙企业完成生物基质特殊输液药房的销售
PR Newswire ·  06/25 11:00

LOS ANGELES, June 25, 2024 /PRNewswire/ -- Triton Pacific Healthcare Partners ("Triton Pacific"), a healthcare-focused private equity group, is pleased to announce the closing of its sale of BioMatrix Specialty Infusion Pharmacy ("BioMatrix" or the "Company") to Frazier Healthcare Partners. Terms of the transaction were not disclosed.

2024年6月25日,洛杉矶 /新华/ -- Triton Pacific Healthcare Partners(Triton Pacific),一家专注于医疗保健的私募股权集团,很高兴宣布已将BioMatrix Specialty Infusion Pharmacy(BioMatrix或公司)出售给Frazier Healthcare Partners。交易条款未披露。

BioMatrix, headquartered in Plantation, FL and serving patients across all 50 states, is one of the largest and most diversified independent providers of specialty infusion services in the U.S. The Company delivers a high-touch, patient-centric model built around therapeutic centers of excellence that provide superior management of patient therapies, including IVIG, bleeding disorders, immunology, neurology, transplant, oncology, and rare diseases.

总部位于佛罗里达州Plantation的BioMatrix,在美国为服务全50个州的患者之一,并且是最大和最多元化独立提供特殊输液服务供应商之一。该公司建立了高接触、以患者为中心的模型,围绕疗效卓越的治疗中心来提供优质的病人治疗管理,包括IVIG、出血性疾病、免疫学、神经学、移植、肿瘤和罕见病等方面的治疗。

Triton Pacific partnered with ACON Investments to acquire BioMatrix in 2016 and, during the course of the investment, worked with the Company to complete five strategic acquisitions. These acquisitions expanded the Company's therapy footprint, added management capabilities, afforded access to new payor contracts, expanded the drug portfolio, and built out infusion operations. In early 2023, BioMatrix divested its lower-margin traditional specialty business and focused intensively on specialty infusion, a high-growth sector propelled by compelling tailwinds. Successfully executing on this strategy, BioMatrix drove exceptional organic growth, with revenue growing roughly five times faster than the broader infusion industry. Throughout Triton Pacific's investment period, BioMatrix has undergone a meaningful evolution, but its commitment to patient care and improved outcomes has remained at the forefront throughout. With an elite management team led by Kathee Kramm and a stellar growth trajectory, BioMatrix is poised for continued success.

Triton Pacific于2016年与ACON Investments合作收购了BioMatrix,并在投资过程中与该公司合作完成了5个战略性收购。 这些收购扩大了公司的治疗范围,增加了管理能力,为新的付款人合同提供了便利,扩大了药物组合,并构建了输液运营。 2023年初,BioMatrix剥离了低利润率的传统特殊业务,集中精力发展特殊输液业务,这是一个由趋势支撑的高增长行业。成功地实施这一策略,BioMatrix推动了卓越的有机增长,收入增长大约比广泛输液行业快五倍。在Triton Pacific的投资期间,BioMatrix经历了有意义的变革,但其致力于病人护理和改善结果的承诺始终处于前沿。由Kathee Kramm领导的精英管理团队以及恒星币的优秀增长轨迹,BioMatrix已经准备继续取得成功。

Kathee Kramm, Chief Executive Officer for BioMatrix, states, "It has been a pleasure to work with Triton Pacific since joining BioMatrix in 2023. The combination of Triton, ACON, and the extremely talented, hardworking staff at BioMatrix have been instrumental in our rapid growth over the last 12 months. The culture at BioMatrix truly revolves around the patient and putting their needs above all else. I am extremely proud of where we are today and very excited to watch the organization continue to reach new highs and unprecedented levels of growth."

BioMatrix首席执行官Kathee Kramm表示:"自2023年加入BioMatrix以来,与Triton Pacific合作一直是一种享受。Triton、ACON以及BioMatrix非常有才华、勤奋的员工的结合,对我们在过去的12个月内实现快速增长起到了决定性的作用。 BioMatrix的文化确实围绕患者展开,在患者需求之上,我为我们今天的业绩感到非常自豪,并且非常激动地看着组织继续跨越新的高峰和前所未有的增长水平。"

Houlihan Lokey, led by Mike Pisani, served as the Company's financial advisor. DLA Piper, led by Josh Kaye, served as the Company's legal counsel.

Houlihan Lokey(由Mike Pisani领导)担任该公司的财务顾问。DLA Piper(由Josh Kaye领导)担任该公司的法律顾问。

About Triton Pacific

关于Triton Pacific

Triton Pacific Capital Partners ( founded in 2001, is a private equity firm offering unique investment opportunities to institutional and high net worth investors. Its healthcare division, Triton Pacific Healthcare Partners, has a dedicated healthcare investment team with a demonstrated track record of successfully sourcing, acquiring, and managing healthcare investments.

Triton Pacific Capital Partners(成立于2001年)是一家为机构和高净值投资者提供独特投资机会的私募股权公司。其医疗保健部门Triton Pacific Healthcare Partners拥有一个专门的医疗保健投资团队,具有成功地寻找、收购和管理医疗保健投资的业绩记录。

Contact:

Joseph I. Davis


Managing Partner


[email protected]

Brian Siegel,IRC,MBA-高级管理董事,Hayden IR,电话:(346)396-8696,ir@zedge.net

Joseph I. Davis


管理合伙人


[email protected]

SOURCE Triton Pacific

消息来源 Triton Pacific

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发